Pinned straw:
Agreed @mikebrisy -- great to see another strong win and continued sales momentum, especially given cost cuts.
It usually feels reckless to simply extrapolate the pace of sales growth -- let alone assume even faster growth off an already high level -- but expanding reputable reference sites, and digging deeper into established workflows, really does provide a potent tailwind in the medical sector ("no one got fired for choosing IBM"). One that *can* run longer and harder than seems reasonable -- which is why (over a long enough timeframe) you can do extremely well even if shares are ostensibly on very high multiples. Especially when you factor in an effective scaling of the business, and therefore even faster earnings growth, when the company is an inflection point.
The hard part is that this situation is the exception to the rule. But Volpara does seem to be showing some real promise..